AMPK Inhibitor

AMPK Inhibitors (48):

Cat. No.	Product Name	Effect	Purity

HY-156397

HTH-02-006	Inhibitor	99.49%
HTH-02-006 is a NUAK2 inhibitor (IC₅₀=126 nM). HTH-02-006 reduces levels of phosphorylated MYPT1 in HuCCT-1 cells. HTH-02-006 inhibits YAP-driven cell proliferation, hepatomegaly and tumorigenesis. HTH-02-006 also has antifibrotic protective effect.

HY-111588

Xanthoangelol	Inhibitor	99.88%
Xanthoangelol, extracted from Angelica keiskei, suppresses obesity-induced inflammatory responses. Xanthoangelol possesses antibacterial activity. Xanthoangelol inhibits monoamine oxidases. Xanthoangelol induces apoptosis in neuroblastoma and leukemia cells.

HY-159480

AD1058	Inhibitor	98.11%
AD1058 is an orally active, selective, and blood-brain barrier permeable inhibitor of ATR. AD1058 exhibits in vivo anticancer activity, inhibiting cell proliferation, disrupting the cell cycle, and inducing Apoptosis. AD1058 can be utilized in research on brain and central nervous system metastases stemming from advanced solid tumors.

HY-101933

MARK-IN-1	Inhibitor	98.48%
MARK-IN-1 is a potent microtubule affinity regulating kinase (MARK) inhibitor with an IC₅₀ of <0.25 nM.

HY-143466

ULK1-IN-2	Inhibitor	99.09%
ULK1-IN-2 (compound 3s) is a potent ULK1 inhibitor. ULK1-IN-2 shows highest cytotoxic effect against cancer cell lines, with IC₅₀ of 1.94 μM in A549. ULK1-IN-2 can induce apoptosis and simultaneously block autophagy, and can be used to study NSCLC (Non-small cell lung cancer).

HY-155943

AMPK-IN-4	Inhibitor
AMPK-IN-4 (compound 19) is a potent inhibitor of (AMPK(α1) and AMPK(α2) with IC₅₀s of 393 nM and 141 nM, respectively. AMPK-IN-4 plays an important role in cancer research.

HY-153797

Dox-btn2	Inhibitor
Dox-btn2 is a biotinylated derivative of Doxorubicin (HY-15142A), with a biotin label at the point of conjugation to doxorubicin at 3'-NH₂. Dox-btn2 can be used for cell imaging. While Doxorubicin is mainly accumulated in the nucleus, while Dox-btn2 is mainly located in the cytoplasm.

HY-161440

SIK-IN-1	Inhibitor	98.91%
SIK-IN-1 (Compound 53) is an inhibitor for salt-inducible kinase (SIK), which inhibits SIK1, SIK2 and SIK3 with IC₅₀s of 0.1, 0.4 and 1.5 nM, respectively. SIK-IN-1 inhibits the release of TNFa with IC₅₀ of 0.5 nM, stimulates the LPS (HY-D1056) -induced IL-10 release with EC₅₀ of 4 nM in human macrophages.

HY-162708

KHKI-01128	Inhibitor	99.95%
KHKI-01128 is a NUAK2 inhibitor, with an IC₅₀ of 0.024 μM. KHKI-01128 exhibits potent anticancer activity against SW480 colorectal cancer cells.

HY-N6794

10Z-Hymenialdisine	Inhibitor
10Z-Hymenialdisine ((Z)-Hymenialdisine) is a natural bioactive pyrrole alkaloid. 10Z-Hymenialdisine is a pan kinase inhibitor, and has anticancer activities.

HY-13418G

Dorsomorphin dihydrochloride (GMP)	Inhibitor
Dorsomorphin dihydrochloride (GMP) is the GMP level of Dorsomorphin dihydrochloride (HY-13418). GMP guidelines are used to produce Dorsomorphin dihydrochloride (GMP). GMP small molecules works appropriately as an auxiliary reagent for cell research manufacture. Dorsomorphin dihydrochloride (GMP) is a potent, selective and ATP-competitive AMPK inhibitor. Dorsomorphin dihydrochloride (GMP) can be used for the research of induced differentiation of pluripotent stem cells (PSCs).

HY-15142A

Doxorubicin	Inhibitor
Doxorubicin (Hydroxydaunorubicin), a broad-spectrum anthracycline antibiotic with cytotoxic properties, is an anti-cancer chemotherapy agent. Doxorubicin has fluorescence properties. Doxorubicin inhibits topoisomerase II with an IC₅₀ of 2.67 μM, thus stopping DNA replication. Doxorubicin reduces basal phosphorylation of AMPK and its downstream target acetyl-CoA carboxylase. Doxorubicin induces apoptosis and autophagy. Doxorubicin inhibits human DNA topoisomerase I with an IC₅₀ of 0.8 μM.

HY-12357S2

Bempedoic acid-d₄	Inhibitor	≥98.0%
Bempedoic acid-d₄ is the deuterium labeled Bempedoic acid. Bempedoic acid (ETC-1002) is an ATP-citrate lyase (ACL) inhibitor. Bempedoic acid (ETC-1002) activates AMPK[1][2].

HY-N3425

Kazinol U	Inhibitor
Kazinol U inhibits melanogenesis through the inhibition of tyrosinase-related proteins via AMPK activation.

HY-120877A

(R)-MRT199665	Inhibitor	98.70%
(R)-MRT199665 is an isomer of MRT199665 (HY-120877). MRT199665 is a potent and ATP-competitive, selective MARK/SIK/AMPK inhibitor with IC₅₀s of 2/2/3/2 nM, 10/10 nM, and 110/12/43 nM for MARK1/MARK2/MARK3/MARK14, AMPKα1/AMPKα2, and SIK1/SIK2/SIK3, respectively. MRT199665 causes apoptosis in MEF2C-activated human acute myeloid leukemias (AML) cells. MRT199665 inhibits the phosphorylation of SIK substrate CRTC3 at S370.

HY-19805A

STO-609 acetate	Inhibitor
STO-609 acetate is a selective and cell-permeable inhibitor of the Ca²⁺/calmodulin-dependent protein kinase kinase (CaM-KK), with K_i values of 80 and 15 ng/mL for recombinant CaM-KKα and CaM-KKβ, respectively. STO-609 acetate inhibits AMP-activated protein kinase kinase (AMPKK) activity in HeLa cell lysates with an IC₅₀ ~0.02 g/ml.

HY-153058

LRRK2-IN-8	Inhibitor
LRRK2-IN-8 is a LRRK2 inhibitor. LRRK2-IN-8 inhibits LRRK2 (wt) and LRRK2 (G2019) with IC₅₀s lower than 10 nM, and inhibits TYK2 and NUAK1 with IC₅₀s of 10-100 nM.

HY-117291

XMD-17-51	Inhibitor
XMD-17-51 is a pyrimido-diazepinone compound that is able to modulate protein kinases.

HY-170380

XY221	Inhibitor
XY221 (Compound 16o) selectively inhibits BRD4 BD2, with an IC₅₀ of 5.8 nM. XY221 demonstrates high pan-BD2 selectivity (667-fold over BRD4 BD1) and BRD4 BD2 domain selectivity (9−32-fold over BRD2/3/T BD2). XY221 induce Apoptosis in MV4-11 cells and shows anticancer activity .

HY-142019

Tanshinol borneol ester	Inhibitor
Tanshinol borneol ester, an angiogenesis stimulator, promoted multiple key steps of angiogenesis through Akt and MAPK signalling pathways. Tanshinol borneol ester has anti-ischemic and anti-atherosclerosis activities.

Name
Email *

	Sorry, but the email address you supplied was invalid.